Fuzeon Drug Development Timeline

John Riley


1 http://patft.uspto.gov US Patent Office
2 ibid.
3 ibid.
4"Potent Suppression of HIV-1 replication in humans by T-0,
a peptide inhibitor of gp41-mediated virus entry," J. Michael Kilby et al., Nature Medicine, vol. 4, No. 11 November 1998
5 "The HIV-1 Cell Entry Inhibitor T-20 Potently Chemoattracts Neutrophils by Specifically Activating the N- Formylpeptide Receptor," Jennifer K. Hartt, et al. NIAID Biohemical and Biophysical Research Communications 272,699- 704 2000
6"Sensitivity of Human Immunodeficiency Virus Type 1 to Fusion Inhibitors Targeted to the gp41 First Heptad Repeat Involves Distinct Regions of gp41 and is Consistently Modulated by gp120 Interactions with the Co-receptor," Cynthia A. Derdeyn et al., J. of Virology, Sept. 2001 p 8605
7"Human Immunodeficiency Virus Type 1 Entry Inhibitors PRO 542 and T-20 Are Potently Synergistic in Blocking Virus-Cell and Cell-Cell Fusion," Kirsten A. Nagashima et al. Journal of Infectious Diseases 2001; 183:1121-1125
8 "Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor" Derdeyn CA et al. J. Virology 75(18):8605-14.2001 Sep;
9"Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro," Tremblay CL, Antimicrob Agents Chemother, 6(5):1336-9, 2002 May;4
10"Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy," Wei X, et. al.Antimicrob Agents Chemother, 46(6):1896-905, 2002 June
11"Long-term treatment with subcutaneous T-20, a fusion inhibitor, in HIV-infected patients: patient satisfaction and impact on activities of daily living." Cohen CJ, AIDS Patient Care & Stds. 16(7):327-35, 2002 Jul
12 "Safety and antiretroviral activity of chronic subcutaneous administration of T-20 in human immunodeficiency virus 1-infected children," Church JA et al. Pediatr Infect Dis J (7):653-9, 2002 July 21
13 "Emergence of resistant Human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20)." Wei X, et al., Antimicrob Agents Chemother 2002 Jun; 46(6): 1896-906
14Analysis of Patient-derived HIV-1 Isolates Suggests a Novel Mechanism for Decreased Sensitivity to Inhibition by Enfuvirtide and T-649 abstract Int AIDS Conf 2002 in Barcelona, Session 73.Poster
16 "Subcutaneous injection survey: psychometric evaluation of a treatment satisfaction instrument associated with a novel HIV medication," Green J, et al., HIV Clin Trials, 3(5):387- 95; 2002 Sep-Oct;
17 "Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics," Reeves JD, Proc Natl Acad Sci USA, 99(25):16249- 54, 2002 Dec 10
18 "Baseline Susceptibility of Primary Human immunodeficiency Virus Type 1 to Entry Inhibitors," Beatrice Labrosse, et al. Journal of Virology, Jan 2003, p 1610-1613 K.S. is a fellow of the ANR

Return to: CPTech Home -> Main IP Page -> IP and Healthcare -> HIV/AIDS -> Fuzeon Page